|
In vitro cytotoxicity | | Ref |
Cell lines | B cell lymphoma SU-DHL | [8, 9] |
| Multiple myeloma OPM-2,U266 | [16, 26] |
| T cell ALL CCRF-CEM-VBL (Vinblastine resistant) | [21] |
| Erythroleukemia K562/Dox(Doxorubicin resistant) | [21] |
Primary tumor cells | Acute myeloid leukemia | [11] |
| Chronic myeloid leukemia | [22, 23] |
| Chronic lymphocytic leukemia | [24, 25] |
| Multiple myeloma | [26] |
|
Mice studies | | |
Cell lines | Human B cell lymphoma Su-DHL | [8, 9] |
| Human cervical cancer HeLa | [30] |
| Murine B cell lymphoma BCL1 | [31, 32] |
Primary tumor cells | Chronic myeloid leukemia | [22] |
| Chronic lymphocytic leukemia | [24] |
|
CIK cells administered with additional manipulation | |
With BsAb | CIK + BSAbxCA125 or BSAbxHER2 versus ovarian primary tumor and cell lines in vitro and in mice | [35] |
| CIK + CD3xHER2/neu bsAb versus Ewing’s family tumor cell lines in vitro and in mice | [36] |
Gene transfection | IL-2 gene electroporated CIK + DC versus pancreatic tumor cell line Dan G | [28] |
| Anti-CD19 chimeric receptor-redirected CIK versus ALL cell line REH and primary ALL cells | [37] |
| Oncolytic virus transfected CIK versus human ovarian cell lines UCI-101 and SK-OV-3 in vitro and in mice | [38] |
|
Clinical studies with demonstrated tumor response | |
Treatment: autologous | Follicular lymphoma (1 case) | [41] |
| Hodgkin’s disease (2 cases) | [42] |
| Renal cell carcinoma (1 case) | [47] |
Treatment: allogeneic | Myelodysplastic syndrome (1 case), Hodgkin’s disease (1 case), Acute myeloid leukemia (1 case) | [49] |
|
Clinical studies in adjuvant setting with demonstrated reduction in relapse | |
Autologous | Acute myelogenous and lymphoblastic leukemia | [44] |
| Hepatocellular carcinoma (intra-arterial) | [46] |
|